Traitements2programmes
Essais1liés
Publications0liées
SourceDBlocale

Traitements

2
MoléculeIndication / populationPhaseObjectifPaysRésultat
WD-1603 Carbidopa-Levodopa Extended-Release TabletsIt is an open-label, balanced, randomized, five-treatment, five-period, five-sequence, multiple oral dose, crossover comparative bioavailability study of different strengths of carbidopa/levodopa extended-release tablets with carbidopa and levodopa tablets in normal, healthy adult human subjects under fasting and fed conditions. The primary objective of the study is to compare the pharmacokinetic profiles between WD-1603 extended-release formulations and carbidopa and levodopa tablets 25mg/100mg following three times a day after oral administration in fasting and fed conditions in healthy subjects and to compare relative bioavailability between treatments. Parkinson Phase 1 À vérifier India À vérifier
WD-1603 Carbidopa-Levodopa Extended-Release TabletsIt is an open-label, balanced, randomized, five-treatment, five-period, five-sequence, multiple oral dose, crossover comparative bioavailability study of different strengths of carbidopa/levodopa extended-release tablets with carbidopa and levodopa tablets in normal, healthy adult human subjects under fasting and fed conditions. The primary objective of the study is to compare the pharmacokinetic profiles between WD-1603 extended-release formulations and carbidopa and levodopa tablets 25mg/100mg following three times a day after oral administration in fasting and fed conditions in healthy subjects and to compare relative bioavailability between treatments. Parkinson Phase 1 À vérifier India À vérifier

Essais cliniques

1
MoléculeIndication / populationPhaseNCTTitreStatut
WD-1603 Carbidopa-Levodopa Extended-Release Tablets Parkinson Phase 1 NCT05128175 Comparative Bioavailability Study of Carbidopa/Levodopa Extended-Release Tablets Under Fasting and Fed Conditions COMPLETED

Publications

0
MoléculeIndication / populationTitreJournalDate
Aucune publication.